سعر يوروتينيب 100 مجم 10 اقراص 2022

Imatinib 100 mg oral tablets, pack of 10.

• Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML): newly diagnosed adults and pediatric patients in chronic phase; and adults in blast crisis, accelerated phase or chronic phase after failure of interferon-alpha therapy.DailyMed (U.S. NLM)
• Ph+ acute lymphoblastic leukemia (adults with relapsed or refractory disease; newly diagnosed pediatric patients in combination with chemotherapy).DailyMed (U.S. NLM)
• Myelodysplastic/myeloproliferative diseases with PDGFR gene rearrangements; aggressive systemic mastocytosis without D816V c-Kit mutation or with unknown status; hypereosinophilic syndrome and/or chronic eosinophilic leukemia; unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans.DailyMed (U.S. NLM)

• Most frequently reported adverse reactions (30% or more): edema, nausea, vomiting, muscle cramps, musculoskeletal pain, diarrhea, rash, fatigue and abdominal pain.International label, equivalent formulation · DailyMed (U.S. NLM)

• None (the US label lists no contraindications).International label, equivalent formulation · DailyMed (U.S. NLM)

• Edema and severe fluid retention; cytopenias (anemia, neutropenia, thrombocytopenia); severe congestive heart failure and left ventricular dysfunction; hepatotoxicity; hemorrhage; gastrointestinal perforation; cardiogenic shock in HES with cardiac involvement; bullous dermatologic reactions; hypothyroidism; embryo-fetal toxicity; growth retardation in children; tumor lysis syndrome; impaired ability to drive; renal toxicity.International label, equivalent formulation · DailyMed (U.S. NLM)

• Strong CYP3A4 inducers (e.g. rifampin, phenytoin, carbamazepine)Decrease imatinib exposure; avoid, or increase the imatinib dose by at least 50% with close monitoring.DailyMed (U.S. NLM)
• Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, grapefruit juice)Increase imatinib concentrations; use caution.DailyMed (U.S. NLM)
• High-dose methotrexate (above 500 mg/m2)Imatinib may delay the clearance of methotrexate when used at high doses.DailyMed (U.S. NLM)

• Can cause fetal harm; advise females of reproductive potential to use effective contraception during treatment and for 14 days after the last dose.International label, equivalent formulation · DailyMed (U.S. NLM)
• Imatinib and its active metabolite are excreted in human milk; advise women not to breastfeed during treatment and for 1 month after the last dose.International label, equivalent formulation · DailyMed (U.S. NLM)

• Imatinib: Small-molecule kinase inhibitor of the BCR-ABL tyrosine kinase and of the PDGF and SCF (c-Kit) receptor tyrosine kinases (US Gleevec label).